Gujarat Themis Biosyn Ltd to Acquire Sanofi's Global Anti-TB and Anti-Infective Portfolio

Gujarat Themis Biosyn Ltd to Acquire Sanofi's Global Anti-TB and Anti-Infective Portfolio​

Mumbai, April 23, 2026: Gujarat Themis Biosyn Ltd. (GTBL), a leading pharmaceutical company specializing in fermentation-based intermediates and active pharmaceutical ingredients (APIs), announced a major strategic move today. The company has entered into an asset purchase agreement to acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi, the French-holding company of the Sanofi group.

The acquisition significantly strengthens GTBL's global pharmaceuticals platform, offering immediate access to regulated and semi-regulated markets. The concern portfolio, which has a strong presence in over 55 countries across Europe, the Middle East, and Africa, includes 13 established branded generic products. These brands reported net sales of approximately EURO 62 million for the financial year ended 2025.

The scope of the transaction is comprehensive, encompassing the acquired brands, marketing authorizations, regulatory dossiers, inventory, and associated commercial rights. Critically, the agreement does not involve the transfer of manufacturing facilities or employees, positioning the expansion as a capital-efficient, assetlight growth strategy for GTBL.

Strategic Value and Future Integration​

For GTBL, this acquisition represents a key step toward achieving global forward integration. By combining its existing capabilities in fermentation-based intermediates and APIs with the acquired finished dosage formulations, the company aims to drive improved realizations across the entire value chain.

Dr. Sachin Patel, Managing Director of GTBL, stated that the acquisition is a strategic milestone for the company’s evolution into a high-margin, fermentation-based pharmaceutical platform. He noted that by controlling the process from fermentation through to the final product, GTBL will minimize supply chain risks and enhance operational efficiency. The move is also aligned with global healthcare trends, emphasizing the critical need to combat tuberculosis and antimicrobial resistance worldwide.

Transaction Financials and Timeline​

The total consideration for the acquisition is set at EURO 158 million, payable in cash at closing. The funding for the deal is expected to come from an optimal mix of debt and equity.

The company anticipates that the transaction will be EPS accretive, supported by profitable branded generics sales, vertical integration, and improved operating leverage.

The expected timeline for the transaction is a close by the end of Q3 FY27 (Quarter Ending 31st December 2026).

Key details of the transaction are summarized below:


GTBL, an India-based pharmaceutical company, develops, manufactures, and markets fermentation-based intermediates and APIs, with a continuing focus on building an integrated and scalable pharmaceutical platform across domestic and international markets.

GUJTHEM Stock Price Movement​

On Thursday, shares of Gujarat Themis Biosyn Limited slipped by 1.50% to settle at ₹324.42. The stock traded on a volume of 29,125 shares, finishing the session within a range established between ₹323.08 and ₹332.45.